S. Apte

发表

Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population

B. George, K. Lakshmi, V. Mathews, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

V. Ramanan, P. Mannucci, F. Rosendaal, 2016, The New England journal of medicine.

Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

A. Ganser, J. Johansson, R. Fanin, 2020, Bone Marrow Transplantation.

Patient blood management in India - Review of current practices and feasibility of applying appropriate standard of care guidelines. A position paper by an interdisciplinary expert group

Y. Mehta, P. Kapoor, A. Gandhi, 2021, Journal of anaesthesiology, clinical pharmacology.

Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature

Aditi Joshi, S. Kannan, S. Apte, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation

G. Lucchini, B. Sharrack, C. Hawkey, 2022, British journal of haematology.

Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India

P. K. Gogoi, V. Raina, S. Apte, 2013, Indian Journal of Medical and Paediatric Oncology.

Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022

C. Hermans, M. Mancuso, S. Apte, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Invasive procedures in patients with haemophilia: Review of low‐dose protocols and experience with extended half‐life FVIII and FIX concentrates and non‐replacement therapies

C. Hermans, E. Santagostino, S. Apte, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Miguel Ángel Martínez, P. Mannucci, E. Santagostino, 2015 .

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

J. Dumont, D. Perry, L. Valentino, 2013, The New England journal of medicine.

Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

C. Hermans, D. Perry, M. Ozelo, 2015, British journal of haematology.

Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study

C. Hermans, H. Chambost, J. Mahlangu, 2013 .

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India

S. Apte, S. Rangarajan, M. John, 2022, Indian Journal of Hematology and Blood Transfusion.

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

J. Dumont, I. Nestorov, D. Perry, 2014, Blood.

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

C. Kempton, D. Quon, M. Makris, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

hemophilia A Phase 3 study of recombinant factor VIII Fc fusion protein in severe

J. Dumont, I. Nestorov, D. Perry, 2014 .

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results

T. Seth, A. Abraham, S. Apte, 2020, Research and practice in thrombosis and haemostasis.

Bilateral, Simultaneous Total Knee Replacement (TKR) Surgery for Hemophilia a with Eloctate (Extended Half Life Product)—A Feasible and Cost Effective Approach

Aditi Joshi, S. Apte, Rajesh Phatale, 2018, Blood.

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India

S. Apte, S. Rangarajan, M. John, 2022, Indian Journal of Hematology and Blood Transfusion.

A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India

B. George, K. Lakshmi, V. Mathews, 2019, Indian Journal of Hematology and Blood Transfusion.

Safety and efficacy of intravenous immunoglobulin (Flebogamma® 10% DIF) in patients with immune thrombocytopenic purpura.

V. Ramanan, S. Apte, C. Ross, 2019, Immunotherapy.

Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies.

V. Ramanan, S. Apte, A. Khojasteh, 2016, Immunotherapy.

The use of a fludarabine‐based conditioning regimen in patients with severe aplastic anemia – a retrospective analysis from three Indian centers

B. George, K. Lakshmi, A. Viswabandya, 2013, Clinical transplantation.

Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia

S. Apte, P. Malhotra, T. Viswanathan, 2022, Indian Journal of Hematology and Blood Transfusion.

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency

F. Peyvandi, T. Lissitchkov, S. Apte, 2018, Journal of thrombosis and haemostasis : JTH.

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

J. Cortes, M. Deininger, G. Verhoef, 2020 .

Correlation of Day 8 Steroid Response with Bone Marrow Status Measured on Days 14 and 35, in Patients with Acute Lymphoblastic Leukemia Being Treated with BFM Protocol

S. Apte, G. Kamat, K. Subramanian, 2019, Indian Journal of Hematology and Blood Transfusion.